Prospective Observational Cohort Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 620
- 试验地点
- 9
- 主要终点
- Pulmonary follow-up sequelae in patients after COVID-19
研究概览
简要总结
Prospective Observational Swiss Cohort Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19.
详细描述
COVID-19 is a coronavirus induced viral pneumonia leading to Acute Respiratory Distress Syndrome. Previous coronavirus infections (SARS and MERS) led to pulmonary fibrosis in up to 30%. Prospective evaluation of lung abnormalities and pulmonary fibrosis after COVID-19 infection is crucial as novel treatments against lung fibrosis of different etiologies are available. No data on pulmonary longterm effects in COVID-19 survivors are currently available. The nation-wide Swiss COVID-19 lung group establishes a meticulously characterized prospective cohort study on pulmonary long-term sequela of patients living in Switzerland.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent.
- •All adult patients with COVID-19 over 18 years.
排除标准
- •Severe mental or physical disability precluding informed consent or compliance with the protocol for prospective data collection.
- •Pregnancy.
结局指标
主要结局
Pulmonary follow-up sequelae in patients after COVID-19
时间窗: 36 months
Number of patients with the long-term pulmonary complications by measuring lung function, exercise testing and radiological Imaging
Evaluation of risk factors for adverse Outcome after COVID-19
时间窗: 36 months
Number of patients with risk factors including comorbidities and other cofactors and correlate them to adverse outcome in patients after COVID-19
次要结局
- Quality of Life after COVID-19(36 months)
- Compare the functional Pulmonary outcome of COVID-19 disease(36 months)
- Compare the radiological Pulmonary outcome of COVID-19 disease(36 months)
- Physical performance after COVID-19 using frailty assessment tests(36 months)
- Microbiota and COVID-19(36 months)
- Physical performance after COVID-19 using Clinical Frailty Scale(36 months)